Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer

Radium-223 (Ra233) prolongs the survival of men with symptomatic bone-predominant metastatic castration-resistant prostate cancer (mCRPC). However, prostate-specific antigen (PSA) response patterns are not closely associated with Ra223 therapy outcomes. Herein, we sought to analyze the impact of Ra223-induced PSA flares on patient outcome. Using a retrospective cohort study of Ra223 treatment in four Ontario/Canada cancer centres, we identified 134 patients grouped into sub-cohorts according to distinct PSA response patterns: (i) initial PSA flare followed by eventual PSA decline; (ii) PSA response (≥30% PSA decrease within 12 weeks of treatment); and (iii) PSA non-response. We analyzed patient characteristics and outcome measures, including overall survival (OS), using the Kaplan-Meier method and log-rank testing. PSA flares were observed in 27 (20.2%), PSA responses in 11 (8.2%), and PSA non-responses in 96 (71.6%) patients. Amongst PSA flare patients, 12 presented with post-flare PSA decreases below baseline and 15 with PSA decreases below the flare peak but above baseline. Although only six flare patients achieved ≥30% PSA decreases below baseline, the median OS of all flare patients (16.8 months, 95% CI 14.9–18.7) was comparable to that of PSA responders and non-responders (p = 0.349). In summary, around 20% of mCRPC patients experience Ra223-induced PSA flares, whose outcome is similar to that of men with or without PSA responses. Further studies are needed regarding suitable biochemical surrogate markers of response to Ra223.

[1]  O. Sartor Circulating tumor DNA biomarkers for response assessment in prostate cancer. , 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  A. Armstrong,et al.  The Value of Phenotypic Precision Medicine in Prostate Cancer , 2022, The oncologist.

[3]  H. Minn,et al.  Radium‐223 dichloride treatment in metastatic castration‐resistant prostate cancer in Finland: A real‐world evidence multicenter study , 2022, Cancer medicine.

[4]  J. Ferlay,et al.  Cancer statistics for the year 2020: An overview , 2021, International journal of cancer.

[5]  P. Caroli,et al.  Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging , 2021, Therapeutic advances in medical oncology.

[6]  G. Sonpavde,et al.  Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis. , 2020, Critical reviews in oncology/hematology.

[7]  G. Tortora,et al.  Biomarkers of response to advanced prostate cancer therapy , 2020, Expert review of molecular diagnostics.

[8]  Liying Zhang,et al.  Population-Based Analysis Of The Use Of Radium-223 For Bone-Metastatic Castration-Resistant Prostate Cancer In Ontario, And Of Factors Associated With Treatment Completion And Outcome , 2019, Cancer management and research.

[9]  T. Todenhöfer,et al.  Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review , 2019, The world journal of men's health.

[10]  P. Friedl,et al.  Radium 223-mediated zonal cytotoxicity of prostate cancer in bone. , 2019, Journal of the National Cancer Institute.

[11]  H. Macapinlac,et al.  Prostate-specific antigen flare induced by 223RaCl2 in patients with metastatic castration-resistant prostate cancer , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  O. Sartor,et al.  Metastatic Prostate Cancer. , 2018, The New England journal of medicine.

[13]  S. Tyldesley,et al.  A population-based study of the use of radium 223 in metastatic castration-resistant prostate cancer: Factors associated with treatment completion. , 2017, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[14]  M. Kattan,et al.  An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223 , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  K. Tabata,et al.  Prostate‐Specific Antigen Flare Phenomenon Induced by Abiraterone Acetate in Chemotherapy‐Naive Patients With Metastatic Castration‐Resistant Prostate Cancer , 2017, Clinical genitourinary cancer.

[16]  R. Vessella,et al.  Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models , 2017, Clinical Cancer Research.

[17]  M. Shiota,et al.  Co‐introduction of a steroid with docetaxel chemotherapy for metastatic castration‐resistant prostate cancer affects PSA flare , 2016, BJU international.

[18]  E. Heath,et al.  Radium-223 in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer. , 2016, Clinical genitourinary cancer.

[19]  M. Liberatore,et al.  Prostate-Specific Antigen Flare Phenomenon During 223Ra-Dichloride Treatment for Bone Metastatic Castration-Resistant Prostate Cancer: A Case Report. , 2016, Clinical genitourinary cancer.

[20]  F. Saad,et al.  Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. , 2015, European urology.

[21]  D. George,et al.  Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report , 2015, BMC Cancer.

[22]  S. Fosså,et al.  Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223 , 2015, Scandinavian journal of urology.

[23]  S. Oudard,et al.  Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer. , 2014, European journal of cancer.

[24]  S. Hong,et al.  Serum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis , 2014, Journal of Cancer Research and Clinical Oncology.

[25]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[26]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[27]  A. Lipton Implications of bone metastases and the benefits of bone-targeted therapy. , 2010, Seminars in oncology.

[28]  T. Nelius,et al.  PSA surge/flare‐up in patients with castration‐refractory prostate cancer during the initial phase of chemotherapy , 2009, The Prostate.

[29]  C. Sternberg,et al.  Prostate‐specific antigen flare phenomenon with docetaxel‐based chemotherapy in patients with androgen‐independent prostate cancer , 2008, BJU international.

[30]  Elizabeth Garrett-Mayer,et al.  Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  C. Tangen,et al.  Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. , 2006, Journal of the National Cancer Institute.

[32]  M. Naoe,et al.  INITIAL EXPERIENCE OF THE ENZALUTAMIDE TREATMENT FOR CASTRATION-RESISTANT PROSTATE CANCER. , 2016, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

[33]  T. Klatte,et al.  Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy , 2007, International Urology and Nephrology.